STROBE Statement—Checklist of items that should be included in reports of ***cross-sectional studies***

	Item No	Recommendation	Page No
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	P2 37-47
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	P2 37-56
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P3 59-80
Objectives	3	State specific objectives, including any prespecified hypotheses	P3 81-87
Methods			
Study design	4	Present key elements of study design early in the paper	P4 102-106
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P4 91-126
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants	P4 115-124
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P5 128-175
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Exposed: P5 128-140 Unexposed: P5 141-175
Bias	9	Describe any efforts to address potential sources of bias	P5 176-178 P10 296-303
Study size	10	Explain how the study size was arrived at	P4 102-108 P5 131-132 Table 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P5 128-175
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	P6 180-202
		(*b*) Describe any methods used to examine subgroups and interactions	NA
		(*c*) Explain how missing data were addressed	P8 230-231 Table 2 footnotes a-b

		(*d*) If applicable, describe analytical methods taking account of sampling strategy	P6 197-200
		(*e*) Describe any sensitivity analyses	P8 237-242
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	NA
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	P8 218-221 Table 2
		(b) Indicate number of participants with missing data for each variable of interest	Table 2
Outcome data	15*	Report numbers of outcome events or summary measures	P8 222-226 Tables 2 and 3
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	P8 227-236 Table 3
		(*b*) Report category boundaries when continuous variables were categorized	NA
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	P8 237-242
Discussion			
Key results	18	Summarise key results with reference to study objectives	P9 245-246 272-273
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P10 287-318
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P9 245-285
Generalisability	21	Discuss the generalisability (external validity) of the study results	P10 320-327
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	NA

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.